Vasorin/ATIA Promotes Cigarette Smoke–Induced Transformation of Human Bronchial Epithelial Cells by Suppressing Autophagy-Mediated Apoptosis

Wenshu Chen *, 1 , Qiong Wang ** , 1 , Xiuling Xu *, Bryanna Saxton *, Mathewos Tessema *, Shuguang Leng *, Swati Choksi , 1 , Steven A. Belinsky *, Zheng-Gang Liu * and Yong Lin *

* Molecular Biology and Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest DR. SE, Albuquerque, NM, 87108, USA; † Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr., Bethesda, MD, 20892, USA

Abstract

BACKGROUND: Escaping cell death pathways is an important event during carcinogenesis. We previously identified anti-TNFα-induced apoptosis (ATIA, also known as vasorin) as an antiapoptotic factor that suppresses reactive oxygen species (ROS) production. However, the role of vasorin in lung carcinogenesis has not been investigated.

METHODS: Vasorin expression was examined in human lung cancer tissues with immunohistochemistry and database analysis. Genetic and pharmacological approaches were used to manipulate protein expression and autophagy activity in human bronchial epithelial cells (HBECs). ROS generation was measured with fluorescent indicator, apoptosis with release of lactate dehydrogenase, and cell transformation was assessed with colony formation in soft agar.

RESULTS: Vasorin expression was increased in human lung cancer tissues and cell lines, which was inversely associated with lung cancer patient survival. Cigarette smoke extract (CSE) and benzo[a]pyrene diol epoxide (BPDE) induced vasorin expression in HBECs. Vasorin knockdown in HBECs significantly suppressed CSE-induced transformation in association with enhanced ROS accumulation and autophagy. Scavenging ROS attenuated autophagy and cytotoxicity in vasorin knockdown cells, suggesting that vasorin potentiates transformation by impeding ROS-mediated CSE cytotoxicity and improving survival of the premalignant cells. Suppression of autophagy effectively inhibited CSE-induced apoptosis, suggesting that autophagy was pro-apoptotic in CSE-treated cells. Importantly, blocking autophagy strongly potentiated CSE-induced transformation.

CONCLUSION: These results suggest that vasorin is a potential lung cancer–promoting factor that facilitates cigarette smoke–induced bronchial epithelial cell transformation by suppressing autophagy-mediated apoptosis, which could be exploited for lung cancer prevention.

Introduction

Lung cancer is a major health concern that is closely associated with cigarette smoke exposure [1,2]. While cigarette smoke carcinogens induce lung cancer via damaging DNA [3], only a small fraction of DNA-damaged cells become malignant, partly because apoptosis eliminates precancerous cells to prevent tumor formation and growth. Meanwhile, carcinogens and proliferation cues activate cell survival mechanisms to counteract cell death. As the success of carcinogenesis depends on the balance of cell death and survival pathways within the
premalignant and cancerous cells, evading apoptosis significantly contributes to carcinogenesis [2,4]. However, tremendous efforts in tackling currently known apoptosis pathways have had limited improvement for cancer prevention [5]. Thus, elucidating novel apoptosis evasion mechanisms in cancer is highly significant for reducing cancer incidence and mortality.

Carcinogens induce production of reactive oxygen species (ROS). Mitochondria are the main site of ROS production during the process of electron leakage along the mitochondrial respiratory chain for energy production. While ROS serve as second messengers for cellular signaling [6], they also damage DNA, lipids, and proteins, contributing to the pathogenesis of cancer. Particularly, DNA damage may generate somatic gene mutations that lead to cancer development. However, excessive ROS are highly toxic, resulting in extensive damage of cellular components and eventually cell death through apoptosis or necrosis [7]. This type of ROS-mediated cell death is assumed to be a protective mechanism against cancer [8,9]. Therefore, restraining ROS in a nontoxic range in premalignant and cancerous cells is crucial for carcinogenesis [7]. Although ROS scavenging by reductases such as superoxide dismutase, catalase, and the cellular redox buffer system GSH/GSSG has been extensively studied [6,10], how ROS is regulated during cigarette smoke—induced lung carcinogenesis is not yet completely elucidated.

We recently identified anti-TNFα-induced apoptosis (ATIA), also known as vasorin, as an antiapoptotic factor that protects cells against TNFα- and hypoxia-induced apoptosis [11]. While it is expressed on the cell membrane and can be secreted [12,13], vasorin also translocates to the mitochondria where it binds to thioredoxin-2 and suppresses ROS production [11]. We and others have previously reported that vasorin is overexpressed and promotes growth in glioblastoma [11,14], while an oncogenic role in hepatoma was also recently proposed [15,16]. However, the role of vasorin in lung carcinogenesis has never been examined. Thus, we hypothesized that vasorin may play an oncogenic role in cells with cigarette smoke—induced genomic damage through suppression of excessive ROS production. This hypothesis was tested by examining vasorin expression in human lung cancer tissues and cell lines and investigating the role of vasorin in cigarette smoke extract (CSE)-induced transformation of human bronchial epithelial cells. The results suggest that vasorin is a potential lung cancer—promoting factor that facilitates cigarette smoke—induced bronchial epithelial cell transformation by suppressing ROS-mediated autophagy and apoptosis.

Materials and Methods

Reagents and Antibodies

Synthesized benzo[a]pyrene diol epoxide (BPDE) was kindly provided by Dr. Shantu Amin (Department of Pharmacology, Penn State College of Medicine, Hershey, PA) [17] and dissolved in anhydrous dimethyl sulfoxide. CSE was prepared as described previously [18] and expressed as total particulate material (μg/mL) for treating cells. Chloroquine diphosphate salt (Cat. No. C6628), wortmannin (W1628), and 3-methyladenine (M9281) were obtained from Sigma (St. Louis, MO). Recombinant human transform growth factor-β (TGF-β) was purchased from eBioscience (San Diego, CA). Primary Antibodies used were anti-vasorin/vasorin (MAB2140; R&D Systems, Minneapolis, MN), ATG-7 (PA5-17216; Thermo Fisher Scientific, Grand Island, NY), β-actin (A2103; Sigma), β-tubulin (T8328; Sigma), LC3B (L7543; Sigma), p62 (610833; BD Biosciences, San Jose, CA), PARP1 (BML-SA248; Enzo Life Sciences, Farmingdale, NY), phospho-Smad2 (3101; Cell Signaling, Danvers, MA), Smad2 (3103; Cell Signaling), and GAPDH (sc-32233; Santa Cruz Technologies, Santa Cruz, CA).

Cell Culture

Immortalized human bronchial epithelial cell (HBEC) lines HBEC-1, HBEC-2, HBEC-13, and small airway epithelial cell (SAEC) line SAEC-30 were kindly provided by Drs. Jerry W. Shay and John D. Minna (University of Texas Southwestern Medical Center, Dallas, TX) [19] and authenticated by short tandem repeat DNA profiling (Genetica DNA Laboratories, Burlington, NC). HBECs were maintained in keratinocyte serum-free medium (K-SFM) (Cat. No. 17005042; Thermo Fisher Scientific) supplemented with 5 μg/mL of human recombinant epidermal growth factor and 50 mg/mL of bovine pituitary extract and antibiotics (100 U/mL of penicillin and 100 μg/mL of streptomycin) in plates coated with FNC Coating Mix (0407; AthenaES, Baltimore, MD). The immortalized human bronchial cell line BEAS-2B was purchased from American Type Culture Collection (ATCC, Manassas, VA) and were cultured in K-SFM with supplements and antibiotics. All lung cancer cell lines were obtained from ATCC and authenticated by Genetica DNA Laboratories.

Establishment of Vasorin Knockdown Stable BEAS-2B Cell Lines

The vasorin shRNA-expressing plasmid was constructed by inserting a synthetic oligonucleotide encoding a hairpin sequence with a 19-nucleotide stem that is homologous to the target sequence of human vasorin, GGCCGGCAACACCCGCATT, and a 9-base loop sequence into pSilencer 4.1-CMV hygro at the BamHI site (OligoEngine). BEAS-2B cells were transfected with pSilencer 4.1-CMV-hygro-vasorinhRNA using FuGENE HD transfection reagent (Promega, Madison, WI) following the manufacturer’s instruction. Cell clones with stable vasorin knockdown were selected with hygromycin (25 μg/mL) and confirmed by western blot. Cells stably transfected with pSilencer 4.1-CMV-hygro were pooled after hygromycin selection and used as negative control.

Small Interference RNA (siRNA) Transfection

Small interfering RNAs (siRNA; SiGenome SMARTpool) for human vasorin, Atg-7, and control were purchased from Dharmacon (Lafayette, CO). Cells were seeded in 12-well plates at about 60–70% confluence overnight and then were transfected with siRNAs using INTERFERin siRNA transfection reagent (Polyplus- transfection, New York, NY) according to the manufacturer’s instructions.

Western Blot

Cells were harvested in M2 buffer (20 mM Tris–HCl, pH 7.6, 0.5% Nonidet P-40, 250 mM NaCl, 3 mM ethylenediaminetetraacetic acid, 3 mM ethylene glycol-bis(2-aminoethyl)-ether)-N,N,N',N'-tetraacetic acid A, 2 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 20 mM β-glycerophosphate, 1 mM sodium vanadate, and 1 μg/ml leupeptin) to obtain total cell lysate. The protein concentration was determined with Bio-Rad protein quantitation kit (Bio-Rad, Hercules, CA). Western blot was carried out according to standard protocol with 10%–12% sodium dodecyl
sulfate—polyacrylamide gels and polyvinylidene difluoride membranes. The protein signal was detected by enhanced chemiluminescence reagent (Millipore). The band intensity was quantified using NIH Image J software with normalization to respective loading controls and expressed as fold changes with the control sample as 1. For LC3B expression, only LC3B-II was normalized to loading controls and quantified.

**Detection of LC3B Puncta**
peGFP-LC3B-expressing plasmid was a gift from Dr. Han-Ming Shen (National University of Singapore). BEAS-2B cells were seeded on tissue slide cover glass and transfected with the plasmid using FuGENE HD. The next day, cells were further transfected with control or vasorin siRNA. Twenty hours after siRNA transfection, cells were treated with CSE for 2 hours, washed with cold phosphate saline buffer and fixed with cold methanol for 5 min in room temperature. Cells were then observed and photographed using a fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany). The GFP puncta were counted and the results expressed as puncta/cells.

**Detection of ROS**
ROS detection using 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA 5 μM; Invitrogen) as an indicator was done as described previously [10]. The indicator was added to cell culture medium for 30 min before the cells were lysed with M2 buffer. ROS levels were measured in cell lysates with a fluorescence plate reader using a fluorescence filter. The readings were normalized to respective protein concentrations.

**Cell Death Assay**
Cell death was detected by the release of lactate dehydrogenase (LDH) in culture medium using CytoTox 96 Non-Radioactive Cytotoxicity Assay kit from Promega [20]. After removing a portion (LDH) in culture medium using CytoTox 96 Non-Radioactive Cytotoxicity Assay kit from Promega [20]. After removing a portion of the media, the lysis buffer from the kit was added to the wells to release total LDH. The average basal readings (OD490) from control cells were subtracted from all the readings and then the results expressed as percentage against individual total LDH reading set as 100. The experiments were carried out in triplicate.

**Colony Formation Assay**
BEAS-2B cells (10³ cells/well in a 6-well plate) were treated with CSE (20 μg/ml) or BPDE (0.2 μM) for 1 hour and then incubated in fresh medium. The treatment was repeated every two days for a total of three treatments. Cells were trypsinized and seeded in soft agar (12-well plate) in duplicate. After two weeks of incubation, colonies in the agar were photographed under microscope in six random and nonoverlaid fields and counted. Colony formation was expressed as colonies/field [10].

**Tissue Array and Immunohistochemistry**
Immunohistochemistry staining using VECTASTAIN ABC Kit and DAB (3,3′-diaminobenzidine) Peroxidase Substrate Kit (Vector Laboratories, Burlingame, CA) and result assessment of human lung cancer tissue array (Imgenex; Novus Biologicals, Centennial, CO) has been described previously [10]. Briefly, the paraaffin-embedded tissue slide was deparaffinized and rehydrated, and then antigens were heat-retrieved followed by 3% H₂O₂ treatment and blocking. After overnight incubation of primary antibody (goat anti-vasorin, R&D systems, 1:100) at 4 °C, further incubation was performed with ABC Kit and color was developed with DAB according to manufacturer's instructions. The staining of vasorin was compared between tumor and corresponding normal bronchial epithelial cells, and a tumor tissue was considered to have “normal expression” when its staining was comparable with that of bronchial epithelial cells, or as “increased expression” when its staining was higher.

**Patient Survival Analysis with TCGA and Online Database**
RNA-seq data for human NSCLC (n = 957) were retrieved from The Cancer Genome Atlas (TCGA) database. The corresponding patients were followed up to 150 months. Data were analyzed for vasorin expression and patient survival by Cox regression with adjustment for covariates that included age, sex, smoking status, and tumor stage. Estimation of the survival function between high versus low gene expression was done with Kaplan—Meier estimator. For the online data (Kaplan—Meiter Plotter, kmplot.com) that combine 7 cohorts (n = 673, GSE19188, GSE29013, GSE30219, GSE31210, GSE3141, GSE37745, and GSE50088), the association of vasorin expression and lung cancer patient survival was analyzed by the Kaplan—Meier plotter online analysis tool [21,22].

**Statistics**
All quantitative data were expressed as mean ± standard deviation. Comparison of two means was performed with two-tailed Student’s t test. For analyzing tissue array results, Fisher's exact test was used. P < 0.05 was considered statistically significant.

**Results**
**Vasorin is Overexpressed in Lung Cancer and Transformed HBECs**
We first examined vasorin expression in human NSCLC by using immunohistochemistry in tissue arrays containing lung cancer and normal lung tissues. A total of 192 NSCLC cases, including 100 squamous cell carcinomas (SqCC), 74 adenocarcinomas (AC), and 18 other types of NSCLC were evaluated. The results revealed that vasorin was overexpressed in cancers compared with normal lung tissue (Figure 1A). Overall, 34.4% of all evaluated NSCLC cases regardless of tumor histology showed increased expression (Figure 1B). Notably, vasorin overexpression was significantly more prevalent in lung AC (52.7%) compared with lung SqCC (21.0%; P < 0.0001, Fisher's exact test, Figure 1B). This may suggest that vasorin abnormality is involved in the pathogenesis of both lung cancer types, although it is more commonly affected in lung AC. Consistently, vasorin expression was increased (two- to five-fold) in 7 of 9 tested NSCLC cell lines as compared with two immortalized HBEC lines. The increased expression of vasorin was detected for both the 110 kD and 72 kD isoforms (both antiapoptotic) we have previously reported [11] (Figure 1C).

**Increased Vasorin Expression is Associated With Poor Survival of Patients With Lung Adenocarcinoma**
The clinical significance of increased vasorin expression in lung cancer was investigated using data from TCGA. Cox regression analysis of lung cancer cases followed up for up to 150 months revealed a significant inverse association between vasorin expression and survival of these patients after adjustment for age, sex, smoking status, and tumor stage [hazard ratio (HR) = 1.34, 95% confidence
interval (CI) 1.02–1.76, \( P = 0.0356, \text{Figure S1A} \). A similar trend was also observed in adenocarcinomas and squamous cell carcinomas from TCGA when analyzed separately using an online analytical tool [https://www.proteinatlas.org/ [25,26]]. With an independent online resource validation [Kaplan–Meier Plotter [21,22]], the inverse association between vasorin expression and survival in patients with lung adenocarcinoma was detected (HR = 1.64, 95% CI = 1.28–2.03, \( P = 6.9 \times 10^{-5}, \text{Figure S1B} \)), although the association in squamous cell carcinomas was unclear. In addition, vasorin overexpression indicates a worse prognosis in both smokers (HR = 1.58, 95% CI = 1.05–2.39, \( P = 0.028 \)) and never smokers (HR = 2.22, 95% CI = 0.95–5.19, \( P = 0.05, \text{Figure S1B} \)) with lung adenocarcinomas [22]. These results suggest that vasorin is a potential tumor-promoting oncoprotein in human lung adenocarcinoma.

**Vasorin Expression in HBECs was Induced by Cigarette Smoke Extract and BPDE**

To explore the role and mechanism of vasorin in lung carcinogenesis, we first examined if cigarette smoke affected its expression in HBECs. CSE strongly induced vasorin expression in a dose-dependent manner in BEAS-2B and HBEC-2 cells (Figure 1D). Similarly, BPDE, the active metabolite of cigarette smoke carcinogen
benzo[a]pyrene that potently transforms HBECs [10,18], strongly induced vasorin expression (Figure S2). In addition, HBEC-2B cells (HBEC-2 cells transformed by BPDE [23,24]), showed a marked constitutively increased vasorin expression (Figure 1E), indicating that the transient increase in vasorin expression by CSE and BPDE was stabilized during transformation and in lung cancer cell lines. These results suggest that cigarette smoke carcinogens induce vasorin expression, which may be involved in the early steps of lung cancer development.

Knockdown of Vasorin Expression Enhances CSE-Induced Cytotoxicity

Because vasorin was identified as an anti-apoptosis factor [11], we examined if it is involved in suppressing CSE-induced cytotoxicity. Stable vasorin knockdown was established in BEAS-2B cells (Figure 2A). While the cytotoxicity of CSE to BEAS-2B cells in general was increased in a dose-dependent manner, the cells with vasorin knockdown showed significantly increased cell death in each of the various CSE doses evaluated (Figure 2B and C). The CSE-induced cytotoxicity was suppressed by the pan-caspase inhibitor z-VAD (Figure 2D), indicating that vasorin inhibits CSE-induced apoptosis in human lung epithelial cells.

Knockdown of Vasorin Expression Suppresses CSE-Induced HBEC Transformation

Transformation of lung epithelial cells represents an early step of lung carcinogenesis, and the capacity to grow in an anchorage-independent manner is an indicator of transformation. Thus, we used the soft-agar colony formation assay and stable vasorin knockdown cells to investigate whether vasorin plays a role in CSE-induced transformation [18,23]. While CSE and BPDE effectively induced control cells to form colonies in soft agar, vasorin knockdown significantly suppressed this effect (Figure 2E and F and Figure S3). Together with the observation that vasorin inhibits CSE-induced apoptosis, these results suggest that vasorin potentiates CSE-induced HBEC transformation by suppressing apoptotic cell death.

Vasorin Knockdown Potentiates CSE-Induced Autophagy Through Cellular ROS Accumulation

Cigarette smoke exposure of lung epithelial cells activates autophagy and mediates apoptosis or survival under certain circumstances [24–29]. Thus, we investigated if vasorin knockdown impacts CSE-induced autophagy. Indeed, exposure of BEAS-2B cells to CSE strongly induced autophagy activation, as demonstrated by the increased LC3B-II and decreased p62 expression (Figure 3A) and
Figure 3. Vasorin inhibits autophagy. (A) BEAS-2B cells were exposed to increasing concentration of CSE for 4 hours. (B) BEAS-2B cells were treated with CSE (20 μg/ml) for 4 hours with or without pretreatment of chloroquine (CQ, 20 μM for 30 min). (C) BEAS-2B cells were treated with increasing concentrations of BPDE for 4 hours. (D, E) Control or stable vasorin knockdown cells were treated with various concentrations of CSE for 4 hours (D), or with 20 μg/ml of CSE for 4 hours without or with CQ (20 μM) pretreatment for 30 min (E). (A, B, C, D, E) Proteins were detected with western blot with β-actin or β-tubulin as loading control. (F) BEAS-2B cells were transfected with pEGFP-LC3B plasmid for 24 hours, and then were further transfected with control or vasorin siRNA (10 nM). The next day, cells were left untreated or treated with 20 μM of CQ for 30 min before CSE (20 μg/ml) exposure for 2 hours. Cells were observed and images recorded under a fluorescence microscope and LC3 puncta counted. *P < 0.05.

Figure 4. Involvement of ROS in vasorin-mediated autophagy. (A) BEAS-2B cells transfected with control or vasorin siRNA (10 nM) for 24 hours were left untreated or treated with CSE for 4 hours. At the last 30 min of treatment, CM-H2DCFDA (5 μM) was added to the cells. The cells were then harvested for ROS detection with a fluorescent plate reader. The readings of fluorescence were normalized to corresponding protein concentrations. Experiments were carried out in triplicate, *P < 0.05. (B) BEAS-2B cells without (control) or with stable vasorin knockdown were treated with NAC (3 mM) 30 min before CSE (20 μg/ml) incubation for 4 hours. Western blot was carried out to detect LC3B with β-actin as loading control. NAC, N-acetylcysteine.
Figure 5. Autophagy contributes to CSE-induced cell death. (A) BEAS-2B cells treated with autophagy inhibitors CQ (20 μM), WTM (1 μM) or 3-MA (10 mM) for 30 min followed by incubation of CSE (20 μg/ml) for 48 hours. Cell death was determined in triplicate samples by LDH release assay. *P < 0.05. (B, C) BEAS-2B cells were transfected with control or Atg-7 siRNA (10 nM) for 24 hours, then treated with CSE (20 μg/ml, B) or BPDE (0.4 μM) for 4 hours (C). PARP cleavage and Atg-7 levels were examined by western blot with β-tubulin as a loading control.

Figure 6. Inhibition of autophagy increases CSE-induced transformation. (A, B) Representative images (A) of colonies in soft agar of BEAS-2B cells untreated, treated with CQ (20 μM), CSE (20 μg/ml), or their combination. Colonies were counted after two weeks of seeding (B). (C and D) HBEC-13 cells were untreated or treated with 3-MA (10 mM, C), or transfected with control or Atg-7 siRNA before the treatment of CSE (20 μg/ml, D). Cells were then seeded in soft agar and colonies counted as in A and B. *P < 0.05.
Suppressing lysosomal protein degradation with chloroquine (CQ) confirmed the increased activity of autophagy by CSE treatment (Figure 3B and F). A similar effect of BPDE on autophagy was also detected (Figure 3C). Of note, while the detection of LC3-I is not very reproducible, which may partly be due to the fact that the anti-LC3 antibody preferably detects LC3-II and that LC3-I is relatively unstable [30], the induction of LC3-II is reproducibly detected in our experiments. These findings, consistent with previous reports [26–29,31–33], indicate that CSE and BPDE activate autophagy in HBECs.

Interestingly, vasorin knockdown strongly increased CSE-induced autophagy, which was detected biochemically and morphologically (Figure 5D–F). Vasorin suppresses ROS accumulation in other cell types such as fibroblasts, and excessive ROS suppresses CSE carcinogen-induced HBEC transformation [10,11]. Thus, we further examined if ROS is involved in vasorin-mediated autophagy regulation in HBEC cells. While the basal ROS level was significantly increased in vasorin knockdown cells, the CSE-induced ROS accumulation was much higher when vasorin was suppressed (Figure 4A), suggesting that vasorin plays a role in retaining ROS at low levels in cells. The ROS scavenger N-acetylcysteine effectively reduced CSE-induced LC-3B-II expression to basal levels in control and vasorin knockdown cells (Figure 4B), suggesting that CSE induces autophagy depending on ROS and that vasorin deficiency promotes CSE-induced autophagy through enhanced ROS accumulation.

**Suppressing Autophagy Inhibits CSE-Induced Cytotoxicity and Potentiates Transformation**

We then examined the role of autophagy in CSE-induced cytotoxicity and transformation. Pharmacological (CQ, wortmannin [WTM] and 3-methyladenine [3-MA]) or genetic (siRNA against Arg-7) autophagy suppression effectively reduced CSE-induced cytotoxicity (Figure 5A), and this was associated with decreased apoptosis as shown by decreased PARP cleavage (Figure 6B). Similarly, BPDE-induced apoptosis was inhibited by autophagy suppression (Figure 5C). These results suggest that autophagy plays a proapoptosis role in the context of CSE-induced cytotoxicity in HBECs. In addition, autophagy inhibition with either CQ and 3-MA or Arg-7 siRNA effectively increased CSE-induced transformation (Figure 6A–D). Together with data that show vasorin suppresses CSE-induced autophagy and apoptosis, these results suggest that vasorin promotes transformation, at least in part, by inhibiting autophagy-mediated apoptosis.

**Discussion**

This study provides evidence that vasorin is a potential lung cancer—promoting factor that facilitates cigarette smoke—induced bronchial epithelial cell transformation. Vasorin expression was increased in a number of human lung cancer tissues, which was inversely associated with lung cancer patient survival. Vasorin expression was also increased in lung cancer cell lines and transformed HBECs. Vasorin knockdown in HBECs significantly suppressed CSE-induced transformation, which was associated with enhanced ROS accumulation and cytotoxicity. Mechanistically, vasorin knockdown potentiated CSE-induced autophagy and apoptosis in an ROS-dependent manner. Suppression of autophagy effectively suppressed CSE-induced apoptotic cell death and potentiated CSE-induced transformation. These results suggest that vasorin is a potential lung cancer—promoting factor, which suppresses autophagy-mediated apoptosis to facilitate CSE-induced bronchial epithelial cell transformation. Taken together, our findings establish a novel lung carcinogenesis mechanism involving vasorin, the vasorin/ROS/autophagy/apoptosis pathway, which could be exploited for preventing lung carcinogenesis.

Although an increasing number of oncogenic gene mutations are being identified in lung cancer, about one-third of patients with lung cancer have no known mutations or aberrant activation of cancer driver genes. Cellular signaling pathways regulating DNA repair, cell proliferation, survival, and death are involved in cancer development. In addition, there are potential cofactors or promoting factors that facilitate driver-mediated carcinogenesis [3]. Our findings suggest vasorin as an endogenous tumor-promoting factor. Vasorin is induced by cigarette smoke to counteract apoptosis, which maintains survival of premalignant cells during cigarette smoke-induced lung epithelial cell transformation. Notably, the inverse association between vasorin expression and patient survival seen in both smokers and nonsmokers suggests that the role of vasorin in human lung cancer development may also apply to lung cancer caused by secondhand cigarette smoke or other environmental carcinogen exposures.

Vasorin suppresses ROS and apoptosis found in mouse embryonic fibroblasts exposed to TNFα or hypoxia [11]. Consistent with this role, vasorin suppressed CSE-induced and ROS-mediated apoptosis in HBECs. It should be noted that vasorin was shown to function as a decoy ligand to suppress TGF-β signaling in vascular smooth muscle cells and some tumor cells [12,34,35]. TGF-β functions as a tumor suppressor in the early stages of carcinogenesis [36,37]. However, TGF-β-induced signaling was not affected by vasorin knockdown in lung cancer cells (data not shown). Thus, inhibition of TGF-β signaling is unlikely to be involved in vasorin’s function in cigarette smoke—induced cell transformation. Although our current results suggest an ROS-related tumor-promoting mechanism, it does not exclude the possibility that the ROS and TGF-β pathways cooperatively contribute to vasorin’s cancer-promoting function. Future in vivo studies are needed to clarify this possibility.

Autophagy is a cellular process for degradation of exhausted, redundant, and unwanted cell components, including proteins and organelles [24,38], which can lead to either cell survival or death depending on context. In general, moderate autophagy maintains cell homeostasis and survival, whereas excessive autophagy exhausts cell components to kill cells [24,38]. In parallel with its contradictory functions in regulating cell survival or death, the role of autophagy in carcinogenesis is believed to be complex: to promote or suppress cancer development [39]. Although cell type- and insult-specific functions of autophagy are observed, it is highly likely that autophagy plays different roles in carcinogenesis in different organs. Although autophagy has been widely studied in lung cancer cell lines, there is no report to date on the role of autophagy in lung epithelial cell transformation and lung cancer initiation. Prior studies suggest the premise that cigarette smoke induces autophagy in lung epithelial cells [25–29,31–33], and our results further show that autophagy suppresses cell transformation, an early step in lung carcinogenesis. This observation is consistent with the general assumption that autophagy suppresses carcinogenesis at early stages [40–44]. Similarly, a most recent report strongly suggests that autophagy restricts chromosomal instability during replicative crisis, and that loss of autophagy function is required for the initiation of cancer [45]. However, it is also believed that autophagy promotes cancer progression at later stages [40–44]. How vasorin in concert with
autophagy activation contributes to lung carcinogenesis needs further
careful delineation with temporal autophagy suppression in vasorin
knockout animals.

As the so-called autophagic death is uncommon, autophagy can
mediate either apoptosis or necrosis in different contexts and circumstances [46,47]. Our observations that vasorin knockdown
strongly potentiated autophagy and suppressing autophagy effectively
attenuated CSE-induced apoptosis suggest that autophagy mediates
cytotoxicity induced by CSE and cigarette smoke carcinogens such as
BPDE through apoptosis to inhibit transformation.

Our results establish a potentially oncogenic role of vasorin in lung
carcinogenesis, and shed lights on the mechanism by which vasorin
facilitates carcinogen-induced transformation. Further studies are
warranted to map the vasorin-mediated pathway in lung cancer
development, which may identify targets that could be exploited for
lung cancer prevention and/or therapy.

**Conflict of interest**
The authors declare no conflict of interest.

**Data availability statement**
The data that support the findings of this study are available from the
corresponding author on reasonable request.

**Acknowledgments**
The authors thank Dr. Shantu Amin (Hershey College of Medicine,
Penn State University) for providing BPDE, and Dr. Han-Ming
Shen (National University of Singapore) for providing pEGFP-
LC3B-expressing plasmid. The vasorin expression and lung cancer
patient survival association results are based on data generated by the
TCGA Research Network (http://cancergenome.nih.gov/) and
Kaplan Meier Plotter (http://kmplot.com/index.php?p¼service&cancer¼lung). This study was supported in part by
grants from National Cancer Institute, National Institutes of Health,
USA (1R21CA193633 and P30CA11800).

**Appendix A. Supplementary data**
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2019.09.001.

**References**

[1] Siegel RL, Miller KD and Jemal A (2017). Cancer statistics. *CA: A Cancer J Clin* **67**, 7–30.

[2] Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA and Anderson RN, et al (2003). Long-term trends in cancer mortality in the
United States, 1930–1998. *Cancer* **97**, 3133–3275.

[3] Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next
generation. *Cell* **144**, 646–674.

[4] Lin Y, Bai L, Chen W and Xu S (2010). The NF-kappaB activation
pathways, emerging molecular targets for cancer prevention and therapy.
*Expert Opin Ther Targets* **14**, 45–55.

[5] Ocker M and Hopfner M (2012). Apoptosis-modulating drugs for improved
cancer therapy. *Eur J Surg Oncol* **48**, 111–120.

[6] Nimmul AS, Taylor LJ and Bar-Sagi D (2003). Redox-dependent
downregulation of Rho by Rac. *Nat Cell Biol* **5**, 236–241.

[7] Sullivan LB and Chandel NS (2014). Mitochondrial reactive oxygen species and cancer. *Cancer Metab* **2**, 17.

[8] Shen HM, Lin Y, Choksi S, Tran J, Jin T and Chang L, et al (2004). Essential roles of receptor-interacting protein and TRAF2 in oxidative stress-
induced cell death. *Mol Cell Biol* **24**, 5914–5922.

[9] Bai L, Xu X, Wang Q, Xu S, Ju W and Wang X, et al (2012). A superoxide-
mediated mitogen-activated protein kinase phosphatase-1 degradation and c-
Jun NH(2)-terminal kinase activation pathway for luteolin-induced lung
cancer cytotoxicity. *Mol Pharmacol* **81**, 549–555.

[10] Wang Q, Chen W, Xu X, Li B, He W and Padilla MT, et al (2013). RIP1
potentiates BPDE-induced transformation in human bronchial epithelial cells
through catalase-mediated suppression of excessive reactive oxygen species.
*Carcinogenesis* **34**, 2119–2128.

[11] Choksi S, Lin Y, Pobeizinskaya Y, Chen L, Park C and Morgan M, et al
(2011). A HIF-1 target, ATTA, protects cells from apoptosis by modulating the
mitochondrial thioredoxin, TRX2. *Mol Cell* **42**, 597–609.

[12] Malapeira J, Esselens C, Bech-Serra J, Canals F and Arribas J (2011).
ADAM17 (TACE) regulates TGFbeta signaling through the cleavage of
vasorin. *Oncogene* **30**, 1912–1922.

[13] Caccia D, Zanetti Domingues L, Miccione F, De Bortoli M, Carniti C and
Mondellini P, et al (2011). Secretome compartment is a valuable source of
biomarkers for cancer-relevant pathways. *J Proteome Res* **10**, 4196–4207.

[14] Man J, Yu X, Huang H, Zhou W, Xiang C and Huang H, et al (2018).
Hypoxic induction of vasorin regulates Notch1 turnover to maintain glioma
stem-like cells. *Cell Stem Cell* **22**, 104–118 e6.

[15] Huang A, Dong J, Li S, Wang C, Ding H and Li H, et al (2015). Exosomal
transfer of vasorin expressed in hepatocellular carcinoma cells promotes
migration of human umbilical vein endothelial cells. *Int J Biol Sci* **11**, 961–969.

[16] Li S, Li H, Yang X, Wang W, Huang A and Li J, et al (2015). Vasorin is a
potential serum biomarker and drug target of hepatocarcinoma screened by
subtractive-EMSA-SELEX to clinic patient serum. *Oncotarget* **6**, 10045–10059.

[17] Guza R, Kotandeniya D, Murphy K, Dissanayake T, Lin C and Giambattista GM, et al (2011). Influence of C5 substituted cysteine and
related nucleoside analogs on the formation of benzo[a]pyrene diol epoxide-
dG adducts at CG base pairs of DNA. *Nucleic Acids Res* **39**, 3988–4006.

[18] Xu X, Padilla MT, Li B, Wells A, Kato K and Tellez C, et al (2014). MUC1 in
macrophage: contributions to cigarette smoke-induced lung cancer. *Cancer Res* **74**, 460–470.

[19] Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y and Pollack J, et al (2004).
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.
*Cancer Res* **64**, 9027–9034.

[20] Wang X, Chen W and Lin Y (2007). Sensitization of TNF-induced
cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. *Biochem Biophys Res Commun* **355**, 807–812.

[21] Szasz AM, Lanczky A, Nagy A, Forster S, Hark K and Green JE, et al (2016).
Cross-validation of survival associated biomarkers in gastric cancer using
transcriptomic data of 1,065 patients. *Onco Targets 7*, 4932–49335.

[22] Gyoryffy B, Surowiak P, Bodzisz J and Lanczky A (2013). Online survival
analysis software to assess the prognostic value of biomarkers using
transcriptomic data in non-small-cell lung cancer. *PLoS One* **8**,e82241.

[23] Xu X, Bai L, Chen W, Padilla MT, Liu Y and Kim KC, et al (2012). MUC1 contributes to BPDE-induced human bronchial epithelial cell transformation
through facilitating EGFR activation. *PLoS One* **7**,e33846.

[24] Mizushima N and Komatsu M (2011). Autophagy: renovation of cells and
organelles. *Cell Stem Cell* **11**, 1046–1052.

[25] Pallet N (2017). Cigarette smoke-induced autophagy: a deadly association?
*Front Cell Dev Biol* **5**, 1–22.

[26] Hwang JW, Chung S, Sundar IK, Yao H, Arunachalam G and Lamb R, et al (2013). Cigarette smoke metabolically promotes
induction of chronic obstructive pulmonary disease. *Arch Biochem Biophys* **573**, 222–230.

[27] Malapeira J, Esselens C, Bech-Serra J, Canals F and Arribas J (2011).
A HIF-1 target, ATIA, protects cells from apoptosis by modulating the
mitochondrial thioredoxin, TRX2. *Mol Cell* **42**, 597–609.

[28] Hwang JW, Chung S, Sundar IK, Yao H, Arunachalam G and Lamb R, et al (2013). Cigarette smoke metabolically promotes
induction of chronic obstructive pulmonary disease. *Arch Biochem Biophys* **573**, 222–230.

[29] Zhu L, Barrett EC, Xu Y, Liu Z, Manoharan A and Chen Y (2013).
Exosomal transfer of vasorin expressed in hepatocellular carcinoma cells promotes
migration of human umbilical vein endothelial cells. *Int J Biol Sci* **11**, 961–969.

[30] Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y and Pollack J, et al (2004).
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.
*Cancer Res* **64**, 9027–9034.

[31] Wang X, Chen W and Lin Y (2007). Sensitization of TNF-induced
cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. *Biochem Biophys Res Commun* **355**, 807–812.

[32] Szasz AM, Lanczky A, Nagy A, Forster S, Hark K and Green JE, et al (2016).
Cross-validation of survival associated biomarkers in gastric cancer using
transcriptomic data of 1,065 patients. *Onco Targets 7*, 4932–49335.

[33] Gyoryffy B, Surowiak P, Bodzisz J and Lanczky A (2013). Online survival
analysis software to assess the prognostic value of biomarkers using
transcriptomic data in non-small-cell lung cancer. *PLoS One* **8**,e82241.

[34] Xu X, Bai L, Chen W, Padilla MT, Liu Y and Kim KC, et al (2012). MUC1 contributes to BPDE-induced human bronchial epithelial cell transformation
through facilitating EGFR activation. *PLoS One* **7**,e33846.
Ryter SW, Chen ZH, Kim HP and Choi AM (2009). Autophagy in chronic obstructive pulmonary disease: homeostatic or pathogenic mechanism? *Autophagy* 5, 235–237.

Kim HP, Wang X, Chen ZH, Lee SJ, Huang MH and Wang Y, et al (2008). Autophagic proteins regulate cigarette smoke-induced apoptotic proteolytic role of heme oxygenase-1. *Autophagy* 4, 887–895.

Chen RJ, Tsai SJ, Ho CT, Pan MH, Ho YS and Wu CH, et al (2012). Chemopreventive effects of pterostilbene on urethane-induced lung carcinogenesis in mice via the inhibition of EGFR-mediated pathways and the induction of apoptosis and autophagy. *J Agric Food Chem* 60, 11533–11541.

Ikeda Y, Imai Y, Kumagai H, Nosaka T, Morikawa Y and Hisaoka T, et al (2004). Vasorin, a transforming growth factor beta-binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. *Proc Natl Acad Sci USA* 101, 10732–10737.

Schreper S, Deuse T, Sultan KR, Haddad M, Boger R and Munzel T, et al (2007). Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides? *Cardiology* 108, 128–137.

Gold LI (1999). The role for transforming growth factor-beta (TGF-beta) in human cancer. *Crit Rev Oncog* 10, 303–360.

Jeon HS and Jen J (2010). TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. *J Thorac Oncol: Off Pub Int Assoc Study Lung Cancer* 5, 417–419.

Todde V, Veenhuis M and van der Klei IJ (2009). Autophagy: principles and significance in health and disease. *Biochim Biophys Acta* 1792, 3–15.

Kubisch J, Turei D, Foldvari-Nagy L, Dunai ZA, Zsakai L and Varga M, et al (2013). Complex regulation of autophagy in cancer - integrated approaches to discover the networks that hold a double-edged sword. *Semin Cancer Biol* 23, 252–261.

Kimmelman AC (2011). The dynamic nature of autophagy in cancer. *Genes Dev* 25, 1999–2010.

Wang RC, Wei Y, An Z, Zou Z, Xiao G and Bhagar G, et al (2012). Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. *Science* 338, 956–959.

Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C and Waguri S, et al (2011). Autophagy-deficient mice develop multiple liver tumors. *Genes Dev* 25, 795–800.

Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K and Hino O, et al (2011). Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. *J Cell Biol* 193, 275–284.

Wei Y, Zou Z, Becker N, Anderson M, Sumpter R and Xiao G, et al (2013). EGFR-mediated beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. *Cell* 154, 1269–1284.

Nassour J, Radford R, Correia A, Fuste JM, Schoell B and Jauch A, et al (2019). Autophagic cell death restricts chromosomal instability during replicative crisis. *Nature* 565, 659–663.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D and Agostinis P, et al (2018). Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. *Cell Death Differ* 25, 486–541.

He W, Wang Q, Srinivasan B, Xu J, Padilla MT and Li Z, et al (2014). A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. *Oncogene* 33, 3004–3013.